Cardiotoxicity of doxorubicin and other anthracycline derivatives

Journal of Nuclear Cardiology

Volumn 7, Issue 1, 2000, Pages 53-62

  Jain, Diwakar ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; MYOSIN ANTIBODY IN 111;

CARDIOTOXICITY; DISEASE COURSE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART MUSCLE BIOPSY; HEART PROTECTION; HUMAN; MORBIDITY; MORTALITY; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SCINTIANGIOGRAPHY;

EID: 0034003590     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2000.103324     Document Type: Article

References (81)

1. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974;80:249-59.
2. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-53.
3. Speth PAJ, Van Hoesel QGCH, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
4. Black DJ, Livingston RB. Antineoplastic drugs in 1990: a review (Part II). Drugs 1990;39:652-73.
5. Saltiel E, McGuire W. Doxorubicin (Adriamycin) cardiomyopathy. West J Med 1983;139:332-41.
6. Singhal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931-6.
7. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP. Doxorubicin cardiotoxicity. Cancer Treat Rev 1982;9:149-64.
8. Singhal PK, Ilikovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
9. Legha SS, Benjamine RS, Mackay B, Ewer M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
10. Lefrak EA, Pitha J, Rosenheim S, Gottleib JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
11. Gehl J, Boesgaard M, Paaske T, Jensen BV, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996;7:687-93.
12. Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV. Doxorubicin and paclitaxel: a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996;23(suppl 11):23-7.
13. Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 1999;26(suppl 3):10-6.
14. Dieras V. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Semin Oncol 1998;25(suppl 12):18-22.
15. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody: a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-18.
16. Gianni L, Myers CE. The role of free radical formation in the cardiotoxicity of anthracycline. In: Muggia FM, Green MD, Speyer JL, editors. Cancer treatment and the heart. 1st ed. Baltimore: Johns Hopkins University Press, 1992:9-46.
17. Hershko C, Pinson A, Link G. Prevention of anthracycline cardiotoxicity by iron chelation. Acta Hematol 1996;95:87-92.
18. Halili-Rutman I, Hershko C, Link G, Rutman AJ, Shainberg A. Inhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin. Biochem Pharmacol 1997;54:211-4.
19. Harada H, Cusack BJ, Olson RD, Stroo W, Azuma J, Hagamuchi T, et al. Taurine deficiency and doxorubicin: interaction with the cardiac sarcolemmal calcium pump. Biochem Pharmacol 1990;39:745-51.
20. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 1990;87:4275-9.
21. Jeyaseelan R, Poizat C, Wu HY, Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy: selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 1997;272:5828-32.
22. Anand S, Verma H, Kumar L, Singh N. Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. Cancer Lett 1995;88:101-5.
23. Zhang J, Clark JR, Herman EH, Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine and inhibition by ICRF-187. J Mol Cell Cardiol 1996;28:1931-43.
24. Herman EH, Zhang J, Hasinoff BB, Clark JR Jr, Ferrans VJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol 1997;29:2415-30.
25. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationship in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-18.
26. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986;46:3722-7.
27. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.
28. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity: report of three cases. Ann Intern Med 1987;106:814-6.
29. Pihkala J, Saarinen UM, Lundstrom U, Virtanen K, Virkola K, Siimes MA, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996;32A:97-103.
30. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, Kengen RA, Elzenga NJ, Schasfoort-van Leeuwen MJ, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996;26:230-7.
31. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
32. Goorin AM, Chauvenet AR, Perez-Atayda AR, Cruz J, McCone R, Lipshutz SE. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990;116:144-7.
33. Alexander J, Dainik N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 1979;300:278-83.
34. Choi BW, Berger HJ, Schwartz PE, Alexander J, Wackers FJTh, Gottschalk A, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.
35. Schwartz RG, Zaret B. Diagnosis and treatment of drug induced myocardial disease. In: Muggia FC, Speyer JL, editors. Cardiotoxicity of anticancer therapy. 1st ed. Baltimore: Johns Hopkins University Press, 1992:173-97.
36. Schwartz RG, McKenzie B, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-18.
37. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin induced congestive heart failure: decreasing incidence with routine use of radionuclide angiocardiography [Abstract]. J Nucl Cardiol 1999;6:S-97.
38. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.
39. Sung RY, Huang GY, Shing MK, Oppenheimer SJ, Li CK, Li CK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 1997;60:239-48.
40. Isner JM, Ferrans VJ, Cohen SR, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy: analysis of 64 patients studied at necropsy. Am J Cardiol 1983;51:1167-74.
41. Druck MN, Gulenchyn KY, Evans WK, Gotlieb A, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984;53:1667-74.
42. Estorch M, Carrio I, Berna L, Martinez-Duncker C, Alonso C, Germa JR, et al. 111In-Antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990;31:1965-9.
43. Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34:1503-7.
44. Jain D, Zaret BL. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity [Editorial]. J Nucl Med 1990;31:1970-4.
45. Narula J, Strauss HW, Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence [Editorial]. J Nucl Med 1993;34:1507-9.
46. Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.
47. Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 1996;3:37-41.
48. Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima J, Nakamura T, et al. Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. J Cardiol 1996;27:49-55.
49. Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 1995;62:542-7.
50. Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998;58:195-7.
51. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury [see comments]. Circulation 1997;96:2641-8.
52. Olson HM, Capen CC. Subacute cardiotoxicity of adriamycin in the rat. Lab Invest 1977;37:386-94.
53. Solcia E, Ballerini L, Bellini O, Margini U, Bertazzoli C, et al. Cardiomyopathy of doxorubicin in experimental animals: factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 1981;67:461-72.
54. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989;63:37-45.
55. Balazsovits JAE, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, et al. Analysis of the effects of liposome encapsulation on the vesicant properties, acute and cardiac toxicities and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 1989;23:81-6.
56. Fitchner I, Arndt D, Elbe B, Reszka R. Cardiotoxicity of free and liposomally encapsulated daunorubicin in mice. Oncology 1984;41:363-9.
57. Forssen EA, Tokes ZA. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A 1981;78:1873-7.
58. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagle dogs by liposomal encapsulation. Cancer Res 1985;43:5427-32.
59. Rahman A, More N, Schein PS. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 1982;42:1817-25.
60. Jain D, Wackers FJ, Welles L, Zaret BL. Reduced cardiotoxicity of liposomal doxorubicin (D99): a phase III single agent study in patients with metastatic breast cancer (MBC) [abstract]. J Am Coll Cardiol 1999;33(suppl A):426A.
61. Rosa P, Clementi F. Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration. Pharmacology 1983;26:221-9.
62. Strom G, Van Hoesel QGCM, de Groot G, Kop W, Steerenberg PA, Hillen FC. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the LOU/M Wsl rat. Cancer Chemother Pharmacol 1989;24:341-8.
63. Gabizon A, Shiota P, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989;81:1484-8.
64. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
65. Herman EH, Ferrans VJ, Sanchez JA. Methods of reducing the cardiotoxicity of anthracyclines. In: Muggia FM, Gren MD, Speyer JL, editors. Cancer treatment and the heart. 1st ed. Baltimore: Johns Hopkins University Press, 1992:114-69.
66. Dorr RT. Cytoprotective agents for anthracyclines [Review]. Semin Oncol 1996;23(suppl 8):23-34.
67. DeLeonardis V, Neri B, Bacalli S, Cinelli P. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. Int J Clin Pharmacol Res 1985;5:137-42.
68. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res 1993;53:4658-64.
69. Dimitrov NV, Zhang ZF, Sun J, Si L, Xu GL, et al. Amelioration of doxorubicin-induced cardiotoxicity by selenium in animals and humans. Proc Am Soc Clin Oncol 1985;4:27.
70. Siveski-Iliskovic N, Kaul N, Singhal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin induced cardiomyopathy. Circulation 1994;89:2829-35.
71. Siveski-Iliskovic N, Hill M, Chow DA, Singhal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-5.
72. Speyer JL, Green MD, Krammer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
73. Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr, Ferrans VJ. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol 1997;40:400-8.
74. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-72.
75. Blum RH. Clinical status and optimal use of the cardioprotectant, dexrazoxane. Oncology 1997;11:1669-78.
76. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32.
77. Malisza KL, Hasinoff BB. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch Biochem Biophys 1995;316:680-8.
78. Imondi AR, Della Torre P, Mazue G, Sullivan TM, Robbins TL, Hagerman LM, et al. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 1996;56:4200-4.
79. Jelic S, Radulovic S, Neskovic-Konstantinovic Z, Kreacic M, Ristovic Z, Bosnjak, et al. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. Support Care Cancer 1995;3:176-82.
80. Shenkenberg TD, Von Hoff D. Mitroxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986;105:67-81.
81. Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G. Potential cardiotoxicity with mitroxantrone. Cancer Treat Rep 1982;66: 1641-3.